LFCR240517C12500
- 0.00
- 0.000.00%
Lifecore Biomedical Newsroom
22NW Fund Also Planned to Nominate Two Class I Directors, But Lifecore Said Only Class II Directors Would Be Up for Election at Aug. Meeting
22NW Fund Also Planned to Nominate Two Class I Directors, But Lifecore Said Only Class II Directors Would Be Up for Election at Aug. Meeting
22NW Fund Nominates Nathaniel Calloway, Matthew Korenberg, Elaine Thibodeau and Beau Garrett as Class II Directors
22NW Fund Nominates Nathaniel Calloway, Matthew Korenberg, Elaine Thibodeau and Beau Garrett as Class II Directors
22NW Fund Submits Lifecore Biomedical Board Nominations
22NW Fund Submits Lifecore Biomedical Board Nominations
Lifecore Biomedical Asset Transfer for Creditor Settlement
Lifecore Biomedical Completes Incremental Liquidity Initiatives
CHASKA, Minn., May 16, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), announced certain
Lifecore Biomedical Changes Executive Incentives to Stock Awards
What Made White Falcon Hold Lifecore Biomedical (LFCR)?
Lifecore Biomedical Faces Nasdaq Delisting Challenges
Express News | Lifecore Biomedical, Inc. Receives Notice From Nasdaq Regarding Delayed Quarterly Report
Do You Believe in the Upside Trajectory of Lifecore Biomedical (LFCR)?
Express News | Lifecore Sees FY24 Revenue $125M-$130M
Lifecore Biomedical Sees FY24 Rev $125M-$130M >LFCR
Lifecore Biomedical Sees FY24 Rev $125M-$130M >LFCR
Press Release: Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress
Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress Year-to-date Results Consistent with Prior Expectations; Experiencing Fiscal Second Half Lift Pro
Lifecore Biomedical Searches for New Auditor for Fiscal Year 2024
Lifecore Biomedical (LFCR) said Tuesday that Ernst & Young LLP declined to be reappointed as the company's independent registered public accounting firm for its fiscal year ending May 26, 2024, follow
Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update
CHASKA, Minn., March 26, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), announced today
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Lifecore Biomedical Announces New CEO and Equity Inducement Plan
Dow Surges 350 Points; Fed Holds Rates Steady
U.S. stocks traded higher toward the end of trading, after the Federal Reserve left rates unchanged. The Dow traded up 0.91% to 39,467.76 while the NASDAQ rose 1.08% to 16,341.42. The S&P 500 also ros
Top Midday Decliners
Lifecore Biomedical (LFCR) said Wednesday it has decided to continue with its standalone strategic plan after evaluating various alternatives, including reviewing more than 75 potential buyers. The co
Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher
U.S. stocks traded mostly flat midway through trading, ahead of interest-rate decision from the Federal Reserve. The Dow traded up 0.03% to 39,123.89 while the NASDAQ fell 0.01% to 16,165.15. The S&P